Celecoxib modulates inflammatory and immunoregulatory gene expression in human monocyte-derived dendritic cells.

Authors

Vida Hashemi, Behzad Baradaran, Bahar Naseri, Javad Masoumi, Elham Baghbani, Nazila Alizadeh, Mahya Zolfaghar Ghoshooni, Arezoo Hosseini

Published in

BMC research notes. Jun 22, 2026. Epub Jun 22, 2026.

Abstract

Dendritic cells (DCs) play a pivotal role in regulating immune responses, influencing both pro-inflammatory and anti-inflammatory environments. Given the critical role of the COX-2/PEG2 pathway in regulating DC maturation and cytokine production, we investigated whether selective COX-2 inhibition by celecoxib could shift human monocyte-derived dendritic cells (mDCs) toward a toerogenic profile. The impact of celecoxib treatment on the expression of various inflammatory and anti-inflammatory factors, including IL-12, TNF-α, IL-10, IDO, TGF-β, and STAT3, was evaluated. Our results demonstrate that the expression of key anti-inflammatory factors was enhanced in DCs, suggesting that COX-2 inhibition could promote a tolerogenic phenotype. In conclusion, the therapeutic modulation of DCs through COX-2 inhibition could have applications beyond autoimmune diseases, offering potential for broader immunomodulatory therapies. Further studies are required to validate these findings and explore clinical applications.

PMID:
42324537
Bibliographic data and abstract were imported from PubMed on 22 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.